Petros Pharmaceuticals Stock EBITDA
| PTPI Stock | USD 0.29 0.02 7.41% |
Petros Pharmaceuticals fundamentals help investors to digest information that contributes to Petros Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Petros Stock. The fundamental analysis module provides a way to measure Petros Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Petros Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -4.2 M | -4.4 M |
Petros | EBITDA |
Petros Pharmaceuticals Company EBITDA Analysis
Petros Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Petros Pharmaceuticals EBITDA | (4.21 M) |
Most of Petros Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Petros Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Petros EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Petros Pharmaceuticals is extremely important. It helps to project a fair market value of Petros Stock properly, considering its historical fundamentals such as EBITDA. Since Petros Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Petros Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Petros Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Petros Ebitda
Ebitda |
|
According to the company disclosure, Petros Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (4.21 Million). This is 100.48% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The ebitda for all United States stocks is 100.11% higher than that of the company.
Petros EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Petros Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Petros Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Petros Pharmaceuticals by comparing valuation metrics of similar companies.Petros Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Petros Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Petros Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Petros Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Petros Pharmaceuticals' value.| Shares | Wells Fargo & Co | 2024-06-30 | 0.0 | Fidelity Management And Research Company | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 | Newbridge Financial Services Group, Inc. | 2024-06-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | Virtu Financial Llc | 2024-06-30 | 70.3 K | Two Sigma Securities, Llc | 2024-06-30 | 53.9 K | Geode Capital Management, Llc | 2024-09-30 | 37.5 K | Vanguard Group Inc | 2024-09-30 | 31.8 K | Blackrock Inc | 2024-06-30 | 16.5 K | Tower Research Capital Llc | 2024-06-30 | 3.3 K |
Petros Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (1.71) % | ||||
| Operating Margin | (1.60) % | ||||
| Current Valuation | 26.75 M | ||||
| Shares Outstanding | 10.01 M | ||||
| Shares Owned By Insiders | 8.10 % | ||||
| Shares Owned By Institutions | 2.20 % | ||||
| Number Of Shares Shorted | 199.19 K | ||||
| Price To Book | 0.87 X | ||||
| Price To Sales | 0.66 X | ||||
| Revenue | 5.82 M | ||||
| Gross Profit | 6.21 M | ||||
| EBITDA | (4.21 M) | ||||
| Net Income | (8.16 M) | ||||
| Cash And Equivalents | 13.3 M | ||||
| Cash Per Share | 0.64 X | ||||
| Total Debt | 8.28 M | ||||
| Debt To Equity | 0.31 % | ||||
| Current Ratio | 3.10 X | ||||
| Book Value Per Share | 4.04 X | ||||
| Cash Flow From Operations | (7.63 M) | ||||
| Short Ratio | 0.72 X | ||||
| Earnings Per Share | (3.80) X | ||||
| Target Price | 1.0 | ||||
| Number Of Employees | 21 | ||||
| Beta | 2.28 | ||||
| Market Capitalization | 2.7 M | ||||
| Total Asset | 33.8 M | ||||
| Retained Earnings | (98.89 M) | ||||
| Working Capital | 9.62 M | ||||
| Net Asset | 33.8 M |
About Petros Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Petros Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Petros Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Petros Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Petros Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Petros Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Petros Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Petros Pharmaceuticals Stock:Check out Petros Pharmaceuticals Piotroski F Score and Petros Pharmaceuticals Altman Z Score analysis. For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Petros Pharmaceuticals. If investors know Petros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Petros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.80) | Revenue Per Share 0.99 | Quarterly Revenue Growth (0.29) | Return On Assets (0.31) | Return On Equity (0.64) |
The market value of Petros Pharmaceuticals is measured differently than its book value, which is the value of Petros that is recorded on the company's balance sheet. Investors also form their own opinion of Petros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Petros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Petros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Petros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Petros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Petros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Petros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.